<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00122603</url>
  </required_header>
  <id_info>
    <org_study_id>2005-003470-20</org_study_id>
    <secondary_id>ANRS 127 2 IP</secondary_id>
    <nct_id>NCT00122603</nct_id>
  </id_info>
  <brief_title>Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)</brief_title>
  <official_title>Efficacy and Safety of Regimens Restricted to a Combination of Two Boosted Protease Inhibitors as Potent Antiretroviral Therapy in HIV-1 Infected Patients. ANRS 127 2IP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Agency for Research on AIDS and Viral Hepatitis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Agency for Research on AIDS and Viral Hepatitis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate virological efficacy and safety of two double
      protease inhibitor regimens: atazanavir/fosamprenavir/ritonavir 300 mg once daily/ 700/100 mg
      twice daily, versus atazanavir/saquinavir/ritonavir 300/1500/100 mg once daily in protease
      inhibitor naive HIV-1 patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this randomized, open-label study is to evaluate virological efficacy and
      safety of two double protease inhibitor regimens: atazanavir/fosamprenavir/ritonavir 300 mg
      once daily/ 700/100 mg twice daily, versus atazanavir/saquinavir/ritonavir 300/1500/100 mg
      once daily in protease inhibitor naive HIV-1 patients.

      Patients with CD4 cell counts over or equal to 200/mm3, HIV viral load between 10,000 and
      750,000 copies per milliliter, and wild-type genotype at baseline will be eligible. This
      multicenter study will enroll 60 patients (n=30 in each group). The planned duration of the
      study is 48 weeks from the enrolment of the last subject.

      The primary efficacy endpoint will be virologic success defined as HIV RNA levels below 50
      copies/ml after 16 weeks of initial treatment. The durability of this response will be
      evaluated and patients will be followed for 48 weeks.

      The primary safety endpoint will be treatment interruptions because of adverse effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virologic success defined as HIV RNA levels below 50 copies/ml after 16 weeks of initial treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of protease inhibitors</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with viral load below 400 copies/ml at week 16 (W16)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index (BMI)</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atazanavir + Fosamprenavir + ritonavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atazanavir + saquinavir + ritonavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosamprenavir</intervention_name>
    <description>ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill twice a day) + FPV (700mg: 1 pill twice a day)</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saquinavir</intervention_name>
    <description>ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill per day) + SQV (500mg: 3 pills per day)</description>
    <arm_group_label>group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Protease inhibitor naive patients

          -  Wild type genotype

          -  CD4 greater than 200/mm3

          -  Viral load between 10,000 copies/ml and 750,000 copies/ml

          -  Signed informed consent

        Exclusion Criteria:

          -  Pregnancy; breast feeding

          -  Antiretroviral (ARV) pretreated patients

          -  Hyperlipidemic treatment

          -  Evolutive disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland Landman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Bichat SMIT A Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Pierre Aboulker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Inserm SC10</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service des Maladies infectieuses et tropicales Hopital Bichat Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2005</study_first_submitted>
  <study_first_submitted_qc>July 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2005</study_first_posted>
  <last_update_submitted>December 21, 2011</last_update_submitted>
  <last_update_submitted_qc>December 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>HIV infections</keyword>
  <keyword>Atazanavir</keyword>
  <keyword>Saquinavir</keyword>
  <keyword>Fosamprenavir</keyword>
  <keyword>ritonavir</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Saquinavir</mesh_term>
    <mesh_term>Fosamprenavir</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

